Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 545

1.

Erratum to "First-line ribociclib plus letrozole for postmenopausal women with HR+, HER2- ABC: MONALEESA-2 safety results" [Breast 36 (Suppl. 1) (November 2017) S44-S45].

Janni W, Chan A, Nusch A, Alba E, Bachelot T, Gil-Gil M, Kattan J, Bourgeois H, El Karak F, Sutradhar S, Miller M, Chandiwana D, Conte P.

Breast. 2018 Aug;40:53. doi: 10.1016/j.breast.2018.04.007. No abstract available.

PMID:
30005916
2.

Patterns of Fertility Preservation and Pregnancy Outcome After Breast Cancer at a Large Comprehensive Cancer Center.

Dieci MV, Ghiotto C, Barbieri C, Griguolo G, Saccardi C, Gangemi M, Pluchinotta A, Di Liso E, Giorgi CA, Giarratano T, Tasca G, Vernaci G, Faggioni G, Conte P, Guarneri V.

J Womens Health (Larchmt). 2018 Jul 2. doi: 10.1089/jwh.2018.6986. [Epub ahead of print]

PMID:
29963941
3.

Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): Towards a less dismal future?

Frega S, Bonanno L, Guarneri V, Conte P, Pasello G.

Crit Rev Oncol Hematol. 2018 Aug;128:19-29. doi: 10.1016/j.critrevonc.2018.05.013. Epub 2018 May 24. Review.

PMID:
29958628
4.

Immune characterization of breast cancer metastases: prognostic implications.

Dieci MV, Tsvetkova V, Orvieto E, Piacentini F, Ficarra G, Griguolo G, Miglietta F, Giarratano T, Omarini C, Bonaguro S, Cappellesso R, Aliberti C, Vernaci G, Giorgi CA, Faggioni G, Tasca G, Conte P, Guarneri V.

Breast Cancer Res. 2018 Jun 22;20(1):62. doi: 10.1186/s13058-018-1003-1.

5.

nab-Paclitaxel Plus Carboplatin or Gemcitabine vs Gemcitabine Plus Carboplatin as First-Line Treatment for Patients With Triple-Negative Metastatic Breast Cancer: Results From the tnAcity Trial.

Yardley DA, Coleman R, Conte P, Cortes J, Brufsky A, Shtivelband M, Young R, Bengala C, Ali H, Eakel J, Schneeweiss A, de la Cruz-Merino L, Wilks S, O'Shaughnessy J, Glück S, Li H, Miller J, Barton D, Harbeck N; tnAcity investigators.

Ann Oncol. 2018 Jun 6. doi: 10.1093/annonc/mdy201. [Epub ahead of print]

PMID:
29878040
6.

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O'Shaughnessy J.

Ann Oncol. 2018 Jul 1;29(7):1541-1547. doi: 10.1093/annonc/mdy155.

PMID:
29718092
7.

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, Denkert C, Schem C, Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart M, von Minckwitz G, Baselga J.

Ann Oncol. 2018 Apr 26. doi: 10.1093/annonc/mdx803. [Epub ahead of print] No abstract available.

PMID:
29701763
8.

Olaparib for the treatment of breast cancer.

Griguolo G, Dieci MV, Guarneri V, Conte P.

Expert Rev Anticancer Ther. 2018 Jun;18(6):519-530. doi: 10.1080/14737140.2018.1458613. Epub 2018 Mar 30.

PMID:
29582690
9.

Prognostic performance of early absence of pupillary light reaction after recovery of out of hospital cardiac arrest.

Javaudin F, Leclere B, Segard J, Le Bastard Q, Pes P, Penverne Y, Le Conte P, Jenvrin J, Hubert H, Escutnaire J, Batard E, Montassier E, Gr-RéAC.

Resuscitation. 2018 Jun;127:8-13. doi: 10.1016/j.resuscitation.2018.03.020. Epub 2018 Mar 12.

PMID:
29545138
10.

Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.

Pasello G, Zago G, Lunardi F, Urso L, Kern I, Vlacic G, Grosso F, Mencoboni M, Ceresoli GL, Schiavon M, Pezzuto F, Pavan A, Vuljan SE, Del Bianco P, Conte P, Rea F, Calabrese F.

Ann Oncol. 2018 May 1;29(5):1258-1265. doi: 10.1093/annonc/mdy086.

PMID:
29514216
11.

Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer.

Darlix A, Griguolo G, Thezenas S, Kantelhardt E, Thomssen C, Dieci MV, Miglietta F, Conte P, Braccini AL, Ferrero JM, Bailleux C, Jacot W, Guarneri V.

J Neurooncol. 2018 Jun;138(2):369-382. doi: 10.1007/s11060-018-2805-9. Epub 2018 Feb 27.

PMID:
29488184
12.

Acute fissuration of a giant splenic artery aneurysm detected by point-of-care ultrasound: case report.

Le Conte P, Trewick D, Pes P, Frampas E, Batard E; Winfocus-France Group.

Crit Ultrasound J. 2018 Feb 1;10(1):5. doi: 10.1186/s13089-018-0086-3.

13.

Biosimilars as a strategy to improve sustainability.

Bria E, Conte P.

ESMO Open. 2017 May 29;2(2):e000192. doi: 10.1136/esmoopen-2017-000192. eCollection 2017. No abstract available.

14.

Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.

O'Shaughnessy J, Petrakova K, Sonke GS, Conte P, Arteaga CL, Cameron DA, Hart LL, Villanueva C, Jakobsen E, Beck JT, Lindquist D, Souami F, Mondal S, Germa C, Hortobagyi GN.

Breast Cancer Res Treat. 2018 Feb;168(1):127-134. doi: 10.1007/s10549-017-4518-8. Epub 2017 Nov 21.

15.

Double inlay plus ventral onlay buccal mucosa graft for simultaneous penile and bulbar urethral stricture.

Favorito LA, Conte PP, Sobrinho UG, Martins RG, Accioly T.

Int Braz J Urol. 2018 Jul-Aug;44(4):838-839. doi: 10.1590/S1677-5538.IBJU.2017.0067.

PMID:
29135409
16.

First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer.

Dieci MV, Guarneri V, Giarratano T, Mion M, Tortora G, De Rossi C, Gori S, Oliani C, Merlini L, Pasini F, Bonciarelli G, Griguolo G, Orvieto E, Michieletto S, Saibene T, Del Bianco P, De Salvo GL, Conte P.

Oncologist. 2018 Mar;23(3):297-305. doi: 10.1634/theoncologist.2017-0322. Epub 2017 Nov 13.

PMID:
29133514
17.

Microstructural and associated chemical changes during the composting of a high temperature biochar: Mechanisms for nitrate, phosphate and other nutrient retention and release.

Joseph S, Kammann CI, Shepherd JG, Conte P, Schmidt HP, Hagemann N, Rich AM, Marjo CE, Allen J, Munroe P, Mitchell DRG, Donne S, Spokas K, Graber ER.

Sci Total Environ. 2018 Mar 15;618:1210-1223. doi: 10.1016/j.scitotenv.2017.09.200. Epub 2017 Nov 8.

PMID:
29126641
18.

Evaluation of a short formation on the performance of point-of-care renal ultrasound performed by physicians without previous ultrasound skills: prospective observational study.

Javaudin F, Mounier F, Pes P, Arnaudet I, Vignaud F, Frampas E, Le Conte P; Winfocus-France study group.

Crit Ultrasound J. 2017 Nov 9;9(1):23. doi: 10.1186/s13089-017-0078-8.

19.

Point-of-care ultrasound during advanced cardiopulmonary resuscitation: Rule of art has to be respected!

Lapostolle F, Le Conte P, Arnaudet I, Javaudin F, Pes P, Petrovic T.

Resuscitation. 2018 Jan;122:e1. doi: 10.1016/j.resuscitation.2017.10.022. Epub 2017 Oct 28. No abstract available.

PMID:
29107675
20.

External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience.

Griguolo G, Jacot W, Kantelhardt E, Dieci MV, Bourgier C, Thomssen C, Bailleux C, Miglietta F, Braccini AL, Conte P, Ferrero JM, Guarneri V, Darlix A.

Breast. 2018 Feb;37:36-41. doi: 10.1016/j.breast.2017.10.006. Epub 2017 Oct 23.

PMID:
29073498
21.

Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?

Attili I, Passaro A, Pavan A, Conte P, De Marinis F, Bonanno L.

Crit Rev Oncol Hematol. 2017 Nov;119:30-39. doi: 10.1016/j.critrevonc.2017.09.007. Epub 2017 Sep 19. Review.

PMID:
29065983
22.

Organic coating on biochar explains its nutrient retention and stimulation of soil fertility.

Hagemann N, Joseph S, Schmidt HP, Kammann CI, Harter J, Borch T, Young RB, Varga K, Taherymoosavi S, Elliott KW, McKenna A, Albu M, Mayrhofer C, Obst M, Conte P, Dieguez-Alonso A, Orsetti S, Subdiaga E, Behrens S, Kappler A.

Nat Commun. 2017 Oct 20;8(1):1089. doi: 10.1038/s41467-017-01123-0.

23.

Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all?

Miglietta F, Dieci MV, Griguolo G, Guarneri V, Conte PF.

Cancer Treat Rev. 2017 Nov;60:100-108. doi: 10.1016/j.ctrv.2017.09.001. Epub 2017 Sep 15. Review.

PMID:
28942029
24.

Recognition and treatment of severe sepsis in the emergency department: retrospective study in two French teaching hospitals.

Le Conte P, Thibergien S, Obellianne JB, Montassier E, Potel G, Roy PM, Batard E.

BMC Emerg Med. 2017 Aug 30;17(1):27. doi: 10.1186/s12873-017-0133-6.

25.

The European Cancer Patient's Bill of Rights, update and implementation 2016.

Højgaard L, Löwenberg B, Selby P, Lawler M, Banks I, Law K, Albreht T, Armand JP, Barbacid M, Barzach M, Bergh J, Cameron D, Conte P, de Braud F, de Gramont A, De Lorenzo F, Diehl V, Diler S, Erdem S, Geissler J, Gore-Booth J, Henning G, Horgan D, Jassem J, Johnson P, Kaasa S, Kapitein P, Karjalainen S, Kelly J, Kienesberger A, La Vecchia C, Lacombe D, Lindahl T, Luzzatto L, Malby R, Mastris K, Meunier F, Murphy M, Naredi P, Nurse P, Oliver K, Pearce J, Pelouchov J, Piccart M, Pinedo B, Spurrier-Bernard G, Sullivan R, Tabernero J, Van de Velde C, van Herk B, Vedsted P, Waldmann A, Weller D, Wilking N, Wilson R, Yared W, Zielinski C, Zur Hausen H, Le Chevalier T, Johnston P.

ESMO Open. 2017 Jan 6;1(6):e000127. doi: 10.1136/esmoopen-2016-000127. eCollection 2016. Review.

26.

Biochar based remediation of water and soil contaminated by phenanthrene and pentachlorophenol.

Rao MA, Di Rauso Simeone G, Scelza R, Conte P.

Chemosphere. 2017 Nov;186:193-201. doi: 10.1016/j.chemosphere.2017.07.125. Epub 2017 Jul 26.

PMID:
28778017
27.

Histology-based Combination Induction Chemotherapy for Elderly Patients with Clinical Stage III Non-small Cell Lung Cancer.

Banna GL, Parra HJS, Castaing M, Dieci MV, Anile G, Nicolosi M, Strano S, Marletta F, Guarneri V, Conte P, Lal R.

Anticancer Res. 2017 Jul;37(7):3723-3728.

PMID:
28668866
28.

Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation.

Carbognin L, Sperduti I, Fabi A, Dieci MV, Kadrija D, Griguolo G, Pilotto S, Guarneri V, Zampiva I, Brunelli M, Orvieto E, Nortilli R, Fiorio E, Parolin V, Manfrin E, Caliò A, Nisticò C, Pellini F, Scarpa A, Pollini GP, Conte P, Tortora G, Bria E.

Breast. 2017 Oct;35:21-26. doi: 10.1016/j.breast.2017.06.005. Epub 2017 Jun 17.

PMID:
28628772
29.

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.

Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P.

N Engl J Med. 2017 Aug 10;377(6):523-533. doi: 10.1056/NEJMoa1706450. Epub 2017 Jun 4. Erratum in: N Engl J Med. 2017 Oct 26;377(17 ):1700.

30.

Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists.

Urso L, Cavallari I, Silic-Benussi M, Biasini L, Zago G, Calabrese F, Conte PF, Ciminale V, Pasello G.

Oncotarget. 2017 Jul 4;8(27):44232-44241. doi: 10.18632/oncotarget.17790.

31.

Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations.

Frega S, Lorenzi M, Fassan M, Indraccolo S, Calabrese F, Favaretto A, Bonanno L, Polo V, Zago G, Lunardi F, Attili I, Pavan A, Rugge M, Guarneri V, Conte P, Pasello G.

Oncotarget. 2017 May 16;8(20):32626-32638. doi: 10.18632/oncotarget.15945.

32.

GD2 expression in breast cancer.

Orsi G, Barbolini M, Ficarra G, Tazzioli G, Manni P, Petrachi T, Mastrolia I, Orvieto E, Spano C, Prapa M, Kaleci S, D'Amico R, Guarneri V, Dieci MV, Cascinu S, Conte P, Piacentini F, Dominici M.

Oncotarget. 2017 May 9;8(19):31592-31600. doi: 10.18632/oncotarget.16363.

33.

A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study).

Gelsomino F, Bertolini F, Luppi G, Spallanzani A, Pettorelli E, Reggiani Bonetti L, Meduri B, Manco G, Conte P, Cascinu S.

Clin Colorectal Cancer. 2017 Dec;16(4):410-415.e1. doi: 10.1016/j.clcc.2017.03.011. Epub 2017 Mar 24.

PMID:
28410832
34.

Diagnostic and prognostic impact of fluorine-18-fluorodeoxyglucose PET/CT in preoperative and postoperative setting of breast cancer patients.

Evangelista L, Cervino AR, Michieletto S, Saibene T, Ghiotto C, Guarneri V, Conte P, Reccia P, Saladini G.

Nucl Med Commun. 2017 Jun;38(6):537-545. doi: 10.1097/MNM.0000000000000671.

PMID:
28410290
35.

Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials.

Dieci MV, Frassoldati A, Generali D, Bisagni G, Piacentini F, Cavanna L, Cagossi K, Puglisi F, Michelotti A, Berardi R, Banna G, Goubar A, Ficarra G, Griguolo G, Conte P, Guarneri V.

Breast Cancer Res Treat. 2017 Jun;163(3):637. doi: 10.1007/s10549-017-4219-3. No abstract available.

PMID:
28374322
36.

Impact Assessment of Urethral Meatus Morphology and Penile Biometry in Transurethral Prostate and Bladder Surgery.

Vieiralves RR, Conte PH, Felici EM, Rodrigues NC, de Souza TA, Sampaio FJ, Favorito LA.

Adv Urol. 2017;2017:6321702. doi: 10.1155/2017/6321702. Epub 2017 Feb 19.

37.

Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials.

Dieci MV, Frassoldati A, Generali D, Bisagni G, Piacentini F, Cavanna L, Cagossi K, Puglisi F, Michelotti A, Berardi R, Banna G, Goubar A, Ficarra G, Griguolo G, Conte P, Guarneri V.

Breast Cancer Res Treat. 2017 Jun;163(2):295-302. doi: 10.1007/s10549-017-4191-y. Epub 2017 Mar 13. Erratum in: Breast Cancer Res Treat. 2017 Jun;163(3):637.

PMID:
28289852
38.

LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab.

Bonanno L, De Paoli A, Zulato E, Esposito G, Calabrese F, Favaretto A, Santo A, Conte AD, Chilosi M, Oniga F, Sozzi G, Moro M, Ciccarese F, Nardo G, Bertorelle R, Candiotto C, De Salvo GL, Amadori A, Conte P, Indraccolo S.

Clin Cancer Res. 2017 Jul 1;23(13):3316-3324. doi: 10.1158/1078-0432.CCR-16-2410. Epub 2017 Jan 24.

39.

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.

Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot X, Burris H 3rd, Petersen JA, Stanzel S, Strasak A, Patre M, Ellis P.

J Clin Oncol. 2017 Jan 10;35(2):141-148. Epub 2016 Nov 7.

40.

Intraperitoneal Chemotherapy in Patients Pretreated for Ovarian Cancer Matched with Patients Treated with Parenteral Chemotherapy.

Nicoletto MO, Casarin A, Baldoni A, Rulli E, Tasca G, Baretta Z, Artioli G, Lombardi G, Cappetta A, Floriani I, Randon G, Valpione S, Litta P, Conte P, Mocellin S, Aliberti C.

Anticancer Res. 2016 Dec;36(12):6541-6546.

PMID:
27919980
41.

Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome.

Griguolo G, Dieci MV, Giarratano T, Giorgi CA, Orvieto E, Ghiotto C, Berti F, Della Puppa A, Falci C, Mioranza E, Tasca G, Milite N, Miglietta F, Scienza R, Conte P, Guarneri V.

J Neurooncol. 2017 Jan;131(2):369-376. doi: 10.1007/s11060-016-2309-4. Epub 2016 Nov 16.

PMID:
27853958
42.

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O'Shaughnessy J.

N Engl J Med. 2016 Nov 3;375(18):1738-1748. Epub 2016 Oct 7.

43.

18F-Fluoroestradiol Positron Emission Tomography in Breast Cancer Patients: Systematic Review of the Literature & Meta-Analysis.

Evangelista L, Guarneri V, Conte PF.

Curr Radiopharm. 2016;9(3):244-257. doi: 10.2174/1874471009666161019144950. Review.

PMID:
27774910
44.

Is there an association between prior anti-inflammatory drug exposure and occurrence of peritonsillar abscess (PTA)? A national multicenter prospective observational case-control study.

Lepelletier D, Pinaud V, Le Conte P, Bourigault C, Asseray N, Ballereau F, Caillon J, Ferron C, Righini C, Batard E, Potel G; French PTA Study Group.

Eur J Clin Microbiol Infect Dis. 2017 Jan;36(1):57-63. doi: 10.1007/s10096-016-2770-1. Epub 2016 Sep 7.

PMID:
27604832
45.

Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial.

Dieci MV, Prat A, Tagliafico E, Paré L, Ficarra G, Bisagni G, Piacentini F, Generali DG, Conte P, Guarneri V.

Ann Oncol. 2016 Oct;27(10):1867-73. doi: 10.1093/annonc/mdw262. Epub 2016 Aug 2.

PMID:
27484801
46.

Lipid dynamics in blended wheat and non-wheat flours breadmaking matrices: Impact on fresh and aged composite breads.

Collar C, Conte P.

Food Sci Technol Int. 2017 Jan;23(1):24-35. Epub 2016 Jul 19.

PMID:
27440156
47.

Cancer Control in Central and Eastern Europe.

La Vecchia C, Conte P.

Oncologist. 2016 Oct;21(10):1161-1162. Epub 2016 Jul 8. No abstract available.

48.

Radiological response and survival in locally advanced non-small-cell lung cancer patients treated with three-drug induction chemotherapy followed by radical local treatment.

Bonanno L, Zago G, Marulli G, Del Bianco P, Schiavon M, Pasello G, Polo V, Canova F, Tonetto F, Loreggian L, Rea F, Conte P, Favaretto A.

Onco Targets Ther. 2016 Jun 21;9:3671-81. doi: 10.2147/OTT.S98435. eCollection 2016.

49.

Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer.

Musolino A, Naldi N, Dieci MV, Zanoni D, Rimanti A, Boggiani D, Sgargi P, Generali DG, Piacentini F, Ambroggi M, Cagossi K, Gianni L, Sarti S, Bisagni G, Ardizzoni A, Conte PF, Guarneri V.

Pharmacogenomics J. 2016 Oct;16(5):472-7. doi: 10.1038/tpj.2016.51. Epub 2016 Jul 5.

PMID:
27378608
50.

Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET).

Jerusalem G, Mariani G, Ciruelos EM, Martin M, Tjan-Heijnen VC, Neven P, Gavila JG, Michelotti A, Montemurro F, Generali D, Simoncini E, Lang I, Mardiak J, Naume B, Camozzi M, Lorizzo K, Bianchetti S, Conte P.

Ann Oncol. 2016 Sep;27(9):1719-25. doi: 10.1093/annonc/mdw249. Epub 2016 Jun 29.

PMID:
27358383

Supplemental Content

Support Center